Experience of using secukinumab in treatment of severe refractory psoriasis: a clinical case
In this article we present a clinical case of a patient with severe psoriasis. We assessed efficacy and safety of secukinumab therapy with 88 weeks follow-up.
Main Authors: | Nikolay V. Kungurov, Yulia V. Keniksfest, Muza M. Kokhan, Tatyana A. Syrneva, Elena V. Grishaeva |
---|---|
Format: | Article |
Language: | English |
Published: |
Limited liability company «Science and Innovations» (Saratov)
2019-06-01
|
Series: | Russian Open Medical Journal |
Subjects: | |
Online Access: | http://www.romj.org/node/266 |
Similar Items
-
Experience in the treatment of psoriasis patients using Apremilast, a selective signalling pathway inhibitor
by: N. V. Kungurov, et al.
Published: (2019-04-01) -
Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
by: Kivelevitch D, et al.
Published: (2019-04-01) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021-01-01) -
Treatment Approaches to Moderate to Severe Psoriasis
by: Paolo Gisondi, et al.
Published: (2017-11-01) -
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01)